Investment Pitches

Pitch Summary:
AACo is Australia’s oldest beef producer, owning ~1% of the nation’s landmass. Two major shareholders (Tavistock 53%, Tattarang 22%) control 75.5% and continue accumulating, limiting free float and suggesting take-private potential. Shares trade at a 45% discount to NTA, the widest since relisting in 2001. Strategy shifted in 2013 toward branded beef, vertical integration, and premiumization, with long-term reinvestment over dividends. Despite cyclical beef and climate risks, Tavistock and Tattarang are long-term holders and could privatize AACo, offering minorities a fair price based on NTA. Valuation is full on EV/normalized earnings, but NTA supports significant upside. Risks: lack of catalyst, shareholder misalignment, succession uncertainty at Tavistock, operational risks (disease, FX, climate). Upside IRR projected 22–34% if taken private near A$2.55 NTA.

BSD Analysis:
Thesis relies on eventual privatization by controlling shareholders. Downside muted by deep NTA discount, though lack of clear timing/catalyst is a risk. Industry headwinds (climate, cyclical beef) persist but land value underpins floor.

Pitch Summary:
Prudential has transformed from a global conglomerate into a Pan-Asian life and health insurer. It is well positioned for structural tailwinds: rising incomes, under-penetrated insurance markets, and aging demographics across Asia. The pitch emphasizes Prudential’s exposure to China, Hong Kong, and Southeast Asia, where demand for protection and wealth products is expanding. Valuation is undemanding relative to peers, reflecting macro/geopolitical concerns. Risks include regulatory changes in China, FX swings, and execution in balancing growth with solvency. Long-term compounding potential remains attractive given its distribution scale and brand recognition.

BSD Analysis:
A high-quality Asian insurer trading at a discount due to near-term macro fears. Structural growth drivers provide multi-decade tailwinds.

Pitch Summary:
Dave is a cash-advance/payday lender app trading at ~35x P/E-25, pitched as a short with 50%+ downside. Unit economics turn negative after CAC for true MTMs is counted; churn is high, and many customers fall into debt traps. TAM (~25m) near saturation with 12.4m members, and competition from Chime, EarnIn, Brigit, MoneyLion drives CAC up. A new mandatory 5% advance fee post-FTC settlement worsens customer economics, risking churn. Plaid/JPM fee hikes may raise costs further. Credit losses could spike quickly given balance-sheet exposure; any macro downturn hits immediately. Stock up 500% in past year on momentum, but insiders selling. Peer comps valued at 11–15x EBITDA, vs. DAVE ~20x. Base case sees fair value ~$95 (60% downside), with limited bull case upside.

BSD Analysis:
Thin moat, CAC-sensitive, debt-trap optics, regulatory risk. Overvalued vs. peers, with asymmetric downside if credit turns or competition intensifies.

Pitch Summary:
LAND, a farmland REIT, is flagged as a short due to leverage, California concentration, and weakening fundamentals. 67% of portfolio in CA (~2.5x market cap) faces water scarcity, labor shortages (immigration raids), and infestations. Leverage is ~14x debt+preferred to EBITDA; dividend uncovered by FFO. NAV fell 27% 2023–24, management stopped reporting appraisals. Occupancy slipping (96% from 100%), with rising vacancies/non-accruals. Preferred issuance is expensive (10% fees). Peers like FPI are exiting CA exposure and marking down assets by 50%. Valuation is ~20x EBITDA, 3.5–4% equity FCF yield, with risks of dividend cut and impairment. Pros: specialty crop mix, redevelopment optionality, secular farmland scarcity. But author argues downside dominates as cash flows weaken.

BSD Analysis:
Bear case strong: high leverage, weakening tenants, CA exposure risks. Dividend at risk, NAV overstated. If impairments accelerate, equity could break prior valuation floors.

Pitch Summary:
Elme Communities, a D.C.-area multifamily REIT, is pitched as a Buffett-style liquidation with 14–26% IRR potential. The company shed legacy office assets, recast itself around defensive middle-income apartments, and trades at a discount to NAV. Management has realigned capital allocation toward multifamily growth, with NOI supported by constrained supply and resilient demand. Debt is manageable and largely fixed, protecting against interest volatility. Market perception lags reality, as peers trade at higher multiples while Elme remains stuck with an “office” discount. The shareholder base is likely to push for realization of intrinsic value through continued asset rotation or strategic alternatives. Risks include regional rent regulation, policy headwinds, or recessionary pressure on tenants. Overall, the setup suggests a rerating or monetization event that drives strong shareholder returns.

BSD Analysis:
Elme is a clean REIT transition story, with potential catalysts from portfolio optimization and capital market recognition. Investors undervalue its focused exposure to multifamily at a time of housing scarcity.

Pitch Summary:
Tronox, a TiO₂ producer, is pitched as a cyclical turnaround with asymmetric upside. Trades at 0.33x book and 2.5x 2026E P/E. Management is executing $125–175m cost savings, idled a high-cost plant, and is transitioning mining to higher-grade ore. 2025 will be weak due to mine transitions, but 2026 EBITDA guided to $630–740m vs. $410–460m in 2025. Upside levers: pent-up TiO₂ demand, tariffs vs. Chinese supply, monazite/REO byproduct monetization. Insiders are buying stock, and Apollo previously bid $27/sh in 2021. Risks: high leverage ($3bn net debt, 4.8x), cyclical exposure, bankruptcy if cycle fails. Base case: 4x upside if turnaround succeeds, 25% chance of wipeout. Author sees expected value ~3x with prudent position sizing.

BSD Analysis:
Highly levered cyclical—binary profile. Execution on cost saves, tariffs, and demand rebound could quadruple equity, but failure risks insolvency. Position sizing and timing critical.

Pitch Summary:
Global Net Lease is a REIT transitioning from an externally managed, low-quality portfolio into a streamlined, internally managed net lease REIT. Since the internalization and merger with RTL, it has disposed ~$3bn in assets, delevered from 8.3x to ~6.5x, and reduced G&A significantly. Remaining assets are mostly single-tenant retail/industrial, with 66% IG tenancy and manageable lease terms. The stock trades at ~7.4x 2025 AFFO vs. peers at 12–15x+, with an 11% covered dividend and buyback activity. Management guides to $0.93 FY25 AFFO, but normalized run-rate AFFO is closer to $1.00. At even 10x, shares imply 25%+ IRR. Risks: lingering office exposure (~25%), leverage still high vs. peers, historic reputation. Mitigants: active deleveraging, quality tenants, capital return. Author suggests rerating or even takeout potential if undervaluation persists.

BSD Analysis:
Classic “bad to good” REIT story: cleaned-up portfolio, lower G&A, deleveraging. Yield and buybacks provide downside cover. Reputational overhang is real but if valuation gap persists, strategic alternatives are plausible.

Pitch Summary:
McGraw Hill, an education content and platform company, is pitched as a short. Despite a strong brand and footprint in textbooks and digital learning, the business faces secular headwinds from free/open content, OER adoption, and intense competition in edtech. Digital transformation has been slow and costly, while enrollment trends in higher education are stagnant or declining. Leverage is significant, limiting flexibility. The pitch argues that the equity is overvalued relative to growth prospects, and margins will compress as pricing power erodes. Risks to the short include potential private equity interest or faster-than-expected digital transition success.

BSD Analysis:
Classic melting-ice-cube in publishing, where digital transition lags disruptive competition. Short risk is a takeout, but core business trends remain negative.

Pitch Summary:
AirSculpt operates luxury clinics offering minimally invasive fat removal, fat transfer, and skin-tightening procedures. Using proprietary technology, the company differentiates itself from traditional cosmetic surgery. Demand is supported by rising interest in aesthetics and willingness to pay for non-invasive procedures. The author highlights AIRS’s clinic-owned model, which captures full economics but requires upfront investment. With shares at depressed levels, upside stems from continued clinic expansion and margin leverage as newer sites mature. Risks include regulatory scrutiny, consumer discretionary downturns, and competitive encroachment from other med-spa operators. If execution is steady, AIRS could compound growth through unit expansion and pricing power.

BSD Analysis:
A niche but growing aesthetics platform, with leverage to secular trends in wellness and non-invasive beauty. Execution on new clinics is critical for scaling economics.

Pitch Summary:
TopGolf Callaway is preparing to spin off or sell its TopGolf Entertainment business by 2026. The pitch suggests that TopGolf is the higher-growth, higher-valuation segment, while legacy golf equipment and apparel remain slower-growing and cyclical. Separation could unlock value by attracting distinct investor bases: growth/internet for TopGolf, steady cash flow for Callaway. Delays in execution remain a risk, but the author believes strategic rationale is sound. At current multiples, MODG trades at a discount to sum-of-parts valuation, implying upside if separation occurs. Risks include consumer discretionary cyclicality, capex intensity at TopGolf venues, and execution risk in timing the spin.

BSD Analysis:
Sum-of-parts unlock is compelling: TopGolf deserves a higher multiple than bundled MODG. Key is management follow-through on separation; delays remain an overhang.

Pitch Summary:
Enerflex is a Canadian energy infrastructure company, with ~70% of EBITDA from contracted leases and services and 30% from equipment and processing solutions. It has gained share as a leading player in compression, processing, and rental equipment, benefitting from scale and integration. Despite cyclical headwinds in upstream capex, its recurring revenue stabilizes cash flows. Management has focused on deleveraging and asset optimization since the Exterran acquisition. The pitch highlights that valuation underestimates the durability of cash flows and operating leverage into a recovery. Risks include commodity price volatility, customer concentration, and execution on integration. With the stock at ~5x EBITDA, re-rating potential exists if investors recognize the resilience of recurring revenue streams.

BSD Analysis:
The mix of contracted earnings and market-leading competitive position gives Enerflex durability. While oilfield services are cyclical, recurring cash flow warrants a premium multiple relative to peers.

Pitch Summary:
Laureate Education has transformed its portfolio into a focused Latin American higher education company, benefiting from favorable demographics, regulatory support, and expanding middle-class demand. After divesting non-core assets, it now operates a streamlined business with strong cash flow and manageable leverage. The thesis argues that valuation remains compelling, with shares undervalued relative to peers and supported by growth visibility in Brazil, Mexico, and Peru. The company is expected to compound earnings steadily while exploring further operational improvements.

BSD Analysis:
The pitch highlights the attractiveness of higher education in Latin America, where structural demand drivers support long-term growth. While risks include political and regulatory shifts, Laureate’s geographic diversification and cost discipline mitigate downside. Investors should view this as a stable compounder rather than a high-growth story, with steady cash flow and deleveraging creating shareholder value. The thesis rests on rerating potential as the market recognizes Laureate’s focused model and consistent earnings growth.

Pitch Summary:
Viper Energy, Inc. owns and acquires mineral and royalty assets in oil and natural gas properties in the Permian Basin. We like Viper’s royalty-based business model, which provides more consistent and lower-risk exposure to energy markets. The model offers greater visibility into asset development, typically a source of uncertainty in the mineral rights or royalty businesses. The stock underperformed during the period when OPEC+ raised production, sending oil prices and related equities lower. The stock further lagged when oil-price spikes spurred by the Israel-Iran conflict were viewed as temporary and failed to stir recovery in Viper and other commodity-related equities. During the period, we maintained our position.

BSD Analysis:
Viper’s low-cost royalty structure provides high-margin exposure to Permian production without capex risk, but macro-driven oil price weakness weighed on sentiment. The long-term thesis remains intact given steady operator drilling activity and strong reserve life. Shares trade at an attractive FCF yield, with upside tied to commodity stabilization and continued acreage acquisitions.

Pitch Summary:
Axogen, Inc. is a leader in the development of technologies focused on peripheral nerve regeneration and repair. The company’s biologically active nerve graft platform reduces procedural risks by eliminating the need for secondary surgical sites. During the quarter, Axogen reported top-line growth of 17% and reaffirmed its full-year guidance for both revenue growth and gross margin. Despite this positive momentum, shares declined following a weaker-than-expected Q1 gross margin of 72%, which came in below the company’s guided range of 73–75%. The shortfall was attributed to a one-time inventory adjustment and ongoing manufacturing transition. We believe the ramp-up of Axogen’s new manufacturing facility positions the company for long-term margin expansion, with the potential to exceed 80% gross margins. Given our conviction in the operational improvement expected in the second half of the year, we added to our position during the period.

BSD Analysis:
Axogen is positioned for multi-year margin expansion as its new facility scales and manufacturing transitions normalize. Strong double-digit revenue growth reflects rising adoption of nerve regeneration solutions with high clinical differentiation. Shares trade at a discount to long-term growth potential, with catalysts including gross margin recovery, broader surgeon adoption, and potential CMS reimbursement updates.

Pitch Summary:
Ranpak Holdings Corp. is a manufacturer of paper-based protective packaging solutions. Among the many things we like about Ranpak is the sustainability of its products, which are environmentally friendly compared to plastic, foam, and other packaging materials. We also like its consumable business model and attractive unit economics. While underlying demand remained strong, the stock fell in the quarter when profitability was pressured by higher input and logistics costs due to unexpected volume spikes. We believe that these issues will prove to be short-lived resulting in improving margins over the course of the year. We trimmed the position during the period as the company’s execution has been mixed; however, we still believe the secular shift from plastics to paper and the increasing adoption of labor-saving packaging automation technologies will provide long-term tailwinds.

BSD Analysis:
Ranpak remains a structurally advantaged ESG-focused packaging supplier with recurring consumable revenue and long-term demand visibility. While margin volatility reflects temporary cost pressures, automation initiatives and operating leverage should restore profitability. Shares trade below intrinsic value versus sustainable packaging peers, offering re-rating potential as execution stabilizes. Key catalysts include easing logistics costs, automation adoption, and pricing improvements.

Pitch Summary:
The Cooper Companies, Inc. is a medical technology firm with two main divisions: CooperVision, a leader in contact lenses, and CooperSurgical, which focuses on women’s health, including reproductive care and fertility. Despite strong quarterly performance and a full-year guidance raise, the stock fell on slightly lowered growth forecasts for the contact lens industry. While still growing faster than the industry, the lower guidance brought a punitive response from investors, a recurring theme for healthcare companies. We maintain confidence in the company’s fundamentals and long-term growth potential, and slightly trimmed our position.

BSD Analysis:
Cooper remains a high-quality compounder with leadership in the global contact lens market and exposure to secular fertility trends. Near-term sentiment weakness reflects modestly reduced market growth expectations rather than deterioration in fundamentals. Shares trade at a discount to historical P/E multiples, offering upside as industry growth normalizes. Catalysts include product launches, margin expansion within CooperSurgical, and stabilization of contact lens demand.

Pitch Summary:
Halozyme Therapeutics, Inc. is a leading drug delivery platform company built around its proprietary and commercially validated ENHANZE® technology. This innovative enzyme enables the subcutaneous delivery of biologics and fluids, transforming hours-long intravenous (IV) infusions into quick injections that can be delivered in just minutes. Shares of Halozyme declined during the period following news that the Centers for Medicare & Medicaid Services (CMS) may reconsider how it classifies reformulated drugs using ENHANZE. Under the proposed change, such formulations may no longer qualify as “new drugs,” potentially subjecting them to Medicare price negotiations earlier than previously expected. While the proposal remains under review, we believe ENHANZE continues to offer meaningful advantages… We slightly reduced our position in the company during the quarter.

BSD Analysis:
Despite platform strength and widespread pharma partnerships, Halozyme faces reimbursement overhang risk that could compress long-term royalty economics. The company’s high-margin royalty model supports strong cash generation, but CMS rule changes may lower future uptake or pricing. Shares trade below intrinsic NPV of partnerships, with upside tied to regulatory clarity and pipeline expansion.

Pitch Summary:
Ziff Davis, Inc. operates businesses in two primary segments: business cloud services and digital media. The company delivered solid results for the quarter, beating revenue and EBITDA expectations while management confirmed annual guidance and called for accelerating quarterly growth. However, shares came under pressure as investors did not see enough evidence of improved organic growth or significant acquisitions. We were encouraged by early signs that the company’s acquisition strategy is beginning to bear fruit and believe it is nearing an inflection point for improved organic growth, which we view as a potential catalyst for investor sentiment. In addition, Ziff Davis recently filed a copyright infringement lawsuit against OpenAI, which could result in a favorable settlement over the intermediate term. We modestly trimmed our position in the company during the period.

BSD Analysis:
Ziff Davis continues to face skepticism around its organic growth trajectory despite improving execution and stable M&A optionality. Shares trade below historical EV/EBITDA averages, reflecting uncertainty in digital advertising and cloud services growth durability. A successful legal outcome or renewed acquisition cadence could reaccelerate sentiment, while improving EBITDA margins offer downside support. Key risks include muted digital ad markets and slower cloud adoption trends.

Pitch Summary:
QuidelOrtho Corp. is a global leader in the medical diagnostics industry. We invested in the third quarter of 2022 following pandemic-related earnings pressure. Our thesis was that Quidel’s 2022 merger with Ortho Clinical Diagnostics positioned the company as a top-tier diagnostics platform with the potential for improved top-line growth, margins, and free cash flow. While the company’s earnings report during the most recent quarter was in line with expectations and guidance was unchanged, the stock struggled due to broader macro concerns. The respiratory business remains soft, and the market has concerns about possible impacts from funding cuts in government health programs. Despite near-term headwinds, we see evidence of business improvements taking place under new leadership, and we maintained our position during the quarter.

BSD Analysis:
QuidelOrtho is positioned for a multi-year recovery as post-pandemic normalization stabilizes test volumes and merger synergies expand margins. The platform’s diversified diagnostic mix reduces cyclicality, while molecular adoption and instrument placements create recurring consumable revenue. Shares trade at a discount to diagnostics peers despite improving free cash flow visibility. Catalysts include synergy realization, new test launches, and easing macro pressures.

Pitch Summary:
Ranpak Holdings Corp. is a manufacturer of paper-based protective packaging solutions. Among the many things we like about Ranpak is the sustainability of its products, which are environmentally friendly compared to plastic, foam, and other packaging materials. We also like its consumable business model and attractive unit economics. While underlying demand remained strong, the stock declined during the quarter when profitability was pressured by higher input and logistics costs due to unexpected volume spikes. We believe that these issues will prove to be short-lived and expect demand strength, combined with labor-saving automation initiatives, to ultimately position the company for margin recovery and eventual expansion. We originally invested… during second quarter of 2025, as we still believe the secular shift away from plastics towards paper and ongoing automation improvements will provide a long-term tailwind.

BSD Analysis:
Ranpak’s model benefits from recurring consumable revenue, rising ESG tailwinds, and structural e-commerce growth. Margin pressures appear transitory, with automation and pricing offering recovery levers. Shares trade below intrinsic value relative to sustainable packaging peers, with catalysts including operating leverage, international expansion, and easing input cost volatility.